Q-omics provides the consensus-scored CCL1 profile across patient tissues and cancer cell-line models. CCL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CCL1 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, CCL1 RNA expression shows 7,044 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, LUAD, and TGCT as cancer lineages where CCL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCL1 survival associations across molecular data types. CCL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCL1 RNA expression–survival associations across cancer types. High CCL1 expression shows unfavorable associations in KIRC and UVM, but favorable associations in SKCM, HNSC, BLCA and READ. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CCL1 RNA expression.
This table summarizes CCL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCL1 shows higher tumor expression in LUAD, THCA, COAD, KIRC, BRCA and KIRP. The LUAD box plot shows higher CCL1 RNA expression in tumor versus normal tissue (log2 FC = +0.620, t-test p < 0.001).
This table shows molecular features associated with CCL1 in patient tissues and cancer cell lines. In patient samples, CCL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
